Repackagers and relabelers, the firms that put generics in new bottles

FDA's National Drug Code Directory lists 47,302 generic drug products, approved under abbreviated new drug applications, that carry openFDA's standardized product fields. In the copy published through openFDA¹ and updated Oct. 30, 2026, 27,241 of them are flagged as coming from the original packager. The other 20,061, or 42 percent, are not. Many of those listings belong to firms that buy finished generics from the companies that made them and put them into new containers under their own labels.

Those firms are repackagers and relabelers. Patients rarely know their names. FDA has described a growing demand in health care settings for tablets and capsules repackaged into single-dose containers, and much of that work falls to these firms. Under federal law they count as manufacturers, with their own registration, their own code in every National Drug Code (NDC), and their own place in recall records.

That last point is what trips people up. A repackaged bottle carries a different NDC from the one in the original manufacturer's recall notice, and often a different expiration date too.

What the regulations say

FDA's registration and listing rules draw the lines. 21 CFR 207.1⁴ defines repacking as "the act of taking a finished drug product or unfinished drug from the container in which it was placed in commercial distribution and placing it into a different container without manipulating, changing, or affecting the composition or formulation of the drug." Relabeling means changing a drug's label or labeling without repacking it, and the definition excludes stickers added only for delivery, customer identification or inventory.

Those roles show up in the NDC. Under 21 CFR 207.33⁵, every listed drug needs a unique NDC whose first segment, the labeler code, is assigned by FDA and runs four, five or six digits. Section 207.41⁶ requires every registrant that manufactures, repacks or relabels a human drug to list it under an NDC with the registrant's own labeler code, even when it also lists the product for a private label distributor. FDA's NDC Directory page⁸ says plainly that a labeler "may be a manufacturer, including a repackager or relabeler, or the entity named on the product label." The same FDA page notes that the agency's move to a uniform 12-digit NDC takes effect March 7, 2033, and our explainer on the NDC number covers the format.

One requirement links the two NDCs. Section 207.53⁷ says a repacker or relabeler must report the "source NDC," the code of each finished drug it received, and tie it to the new NDCs it created. That mapping is how FDA can follow a recalled lot from the original maker into a repackaged bottle.

Pharmacies sit under a separate policy. In a January 2017 guidance⁹, FDA said it would not generally take action against state-licensed pharmacies, federal facilities and outsourcing facilities that repackage approved drugs if they meet a list of conditions, including repackaging by or under the direct supervision of a licensed pharmacist, carrying over any storage instructions such as "protect from light," and assigning a beyond-use date. FDA said it does not treat a pharmacy counting out tablets from a stock bottle to fill one patient's prescription as repackaging for purposes of that guidance.

The 2013 Drug Supply Chain Security Act adds tracing duties. The law defines a repackager¹¹ as a firm that "repacks and relabels a product or package" for further sale or for distribution without a further transaction. Under the statute's repackager section¹², those firms had to start printing a product identifier on each package by five years after Nov. 27, 2013, keep transaction records for six years, and, when FDA or a state official asks during a recall, produce tracing information within one business day and no more than 48 hours. Our explainer on the DSCSA covers the rest.

How repackaged expiration dates are set

A repackaged tablet often carries a shorter expiration date than the stock bottle it came from. Federal manufacturing rules tie an expiration date to stability testing in the container the drug is sold in, and a repackager's blister or vial is a new container. FDA's July 2020 guidance¹⁰ on unit-dose repackaging of solid oral drugs offers a shortcut. FDA said it generally would not take action over missing stability studies if the repackaged product's expiration date is no later than six months from repackaging or 25 percent of the time left on the original manufacturer's date, whichever is shorter, and if the container meets USP moisture standards, light-sensitive drugs keep equal protection, the original bottle was unopened and emptied in one operation, and storage matched the original label.

In practice the resulting shelf life can be short. A bottle repackaged with 24 months left before its expiration date gets at most six months, since 25 percent of 24 is six. A bottle with 12 months left gets three. Our explainer on drug expiration dates covers how the original dates are set.

What the NDC data show

openFDA's field definition for the original-packager flag describes it as "Whether or not the drug has been repackaged for distribution," according to the openFDA NDC field reference². GxRadar counted generic (ANDA) listings with openFDA's standardized fields on Nov. 3, 2026, splitting those flagged as original packager from those without the flag. The 20,061 unflagged generic listings belonged to 252 labelers, and the 10 largest held 65 percent of them. The single largest had 4,011.

Counts include combination products whose generic name contains the drug, and a count of listings says nothing about sales volume. Antibiotics stand out. Cephalexin and amoxicillin have roughly four and three unflagged listings, respectively, for each original-packager listing.

How repackagers show up in recalls

When a manufacturer recalls a lot, each repackager that bought it usually has to recall its own versions, under its own NDCs. FDA's enforcement records³ carry the repackager's product description, which sometimes names the original maker and the source NDC and sometimes does not.

GxRadar searched 18,076 drug recall records from June 2012 through Oct. 28, 2026, for product descriptions that say "repackaged," "repacked" or "relabeled." We found 133, a floor, since many repackager recalls never use the word. Labeling errors, manufacturing-practice (CGMP) problems, impurities and sterility concerns were the most common stated reasons. Ten involved valsartan, losartan or irbesartan, six of them in 2018, the year the valsartan recall began.

For anyone checking a medicine against a recall notice, the source NDC is the bridge. Which manufacturer's lot went into a repackaged bottle is a fair question for the pharmacy that dispensed it, and GxRadar's guide to checking whether a medicine was recalled and our recall data cover the rest. The NDC format itself changes on March 7, 2033, when FDA's uniform 12-digit code takes effect and every labeler, repackagers included, moves to the new structure.